Radiation Therapy Clinical Trial
Official title:
Active Symptom Monitoring in Patients Undergoing Radiation Therapy for Thoracic Malignancies
| NCT number | NCT04324645 |
| Other study ID # | 202003007 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | September 3, 2020 |
| Est. completion date | March 13, 2022 |
| Verified date | April 2022 |
| Source | Washington University School of Medicine |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
This study seeks to achieve two aims: - To assess the implementation of Noona software for continuous symptom monitoring for a diverse population of patients with thoracic malignancies who are undergoing radiation and - To validate remote collection of standardized PRO measures using Noona software.
| Status | Completed |
| Enrollment | 36 |
| Est. completion date | March 13, 2022 |
| Est. primary completion date | March 13, 2022 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Biopsy confirmed cancer. Radiographically apparent (i.e. not histologically or cytologically confirmed) malignancy of the thorax is allowed. - Currently planning to receive radiotherapy with or without chemotherapy for greater than one fraction. - Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable). - Age 18 years or older Exclusion Criteria: -Unable to reliably access and use a device compatible with Noona software. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Washington University School of Medicine | Saint Louis | Missouri |
| Lead Sponsor | Collaborator |
|---|---|
| Washington University School of Medicine | Varian Medical Systems |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Percentage of invited symptom reports completed during the study period | Treatment through 90 days of follow-up (estimated to be 5 months) | ||
| Primary | Percentage of questions completed within each invited symptom report | Treatment through 90 days of follow-up (estimated to be 5 months) | ||
| Secondary | Patient reported outcomes as measured by EORTC QLQ-C30 | It includes five function domains (physical, emotional, social, role, cognitive), eight symptoms (fatigue, pain, nausea/vomiting, constipation, diarrhea, insomnia, dyspnea, and appetite loss), as well as global health/quality-of-life and financial impact. Patients respond on a four-point scale from "not at all" to "very much" for most items. Most items use a "past week" recall period. Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function and higher levels of symptom burden. | Baseline, within 1 week of completing therapy and at 90-day follow-up | |
| Secondary | Patient reported outcomes as measured by NCCN Distress Thermometer | Measures distress experienced during the past week. 10 = extreme distress and 0=no distress | Baseline, within 1 week of completing therapy and at 90-day follow-up |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04776083 -
Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients
|
Phase 3 | |
| Completed |
NCT01635270 -
Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma
|
Phase 2 | |
| Terminated |
NCT03724422 -
HO Prophylaxis Therapy for Distal Humerus Fractures
|
N/A | |
| Recruiting |
NCT03731130 -
Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant Radiation or Chemoradiation Followed by Surgery in Patients With Rectal Cancer
|
||
| Recruiting |
NCT04983095 -
Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT05721053 -
Improving Outcomes for Older Adults Undergoing Radiation Therapy
|
||
| Active, not recruiting |
NCT04764227 -
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
|
Phase 2 | |
| Not yet recruiting |
NCT05821452 -
Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05335148 -
Study to Evaluate the Safety of Colchicine
|
Phase 1 | |
| Recruiting |
NCT04362306 -
Radiation Oncology Patient Medical Physics Intervention Study
|
N/A | |
| Completed |
NCT01917890 -
Radiosensitizing and Radioprotectve Effects of Curcumin in Prostate Cancer
|
N/A | |
| Not yet recruiting |
NCT05648253 -
Hyivy Device in Post-radiation Patients
|
N/A | |
| Completed |
NCT03235427 -
The CAROLE (CArdiac Related Oncologic Late Effects) Study
|
||
| Recruiting |
NCT03142425 -
Blood Test to Predict Radiation Response and Toxicity in Patients Undergoing Radiation Therapy
|
||
| Recruiting |
NCT05406063 -
Stereotactic Multiple Fraction Radiotherapy for Non-spine Bone Metastases
|
N/A | |
| Recruiting |
NCT03213925 -
Neoadjuvant Chemotherapy Followed by Radiotherapy Alone in Patients With Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT03071289 -
A Trial Comparing Observation With Radiation on Pelvic Lymphocysts After Radical Hysterectomy of Cervical Cancer
|
Phase 3 | |
| Recruiting |
NCT06128863 -
Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial
|
Phase 2 | |
| Recruiting |
NCT05351294 -
Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet
|
Phase 3 | |
| Recruiting |
NCT05817201 -
Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy
|
Phase 2/Phase 3 |